Type 2 & other diabetes

The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus

Diabetes Obes MetabPublished Propensity score-matched cohort study

Main finding · Any fractureResult — go to the resultAdjusted hazard ratio 1.09 95% CI 0.91–1.31

Authors' conclusion

Use of SGLT2 inhibitors was not associated with the risk of any fracture, MOFs or fracture at the individual MOF sites when compared to DPP-4 inhibitor use.

Study context

Population
Patients aged ≥18 years with T2D starting a DPP-4i or SGLT2i as add-on to metformin, January 1, 2013–June 30, 2020, Clinical Practice Research Datalink (CPRD) Aurum databasematched cohort
Participants
13,807 vs 28,524
Exposure
SGLT2i vs DPP-4i as add-on to metformin
  • SGLT2 inhibitorn = 13,807
  • DPP-4 inhibitorn = 28,524reference
Outcome
Any fracture or major osteoporotic fractures (MOFs)
Methodological detailspropensity-score matched (up to 1:3), Cox proportional hazard models
  • Propensity-score matched (up to 1:3)
  • Cox proportional hazard models

Main finding

Any fracture

Adjusted hazard ratio

1.09

95% CI 0.91–1.31

SGLT2 inhibitorvs DPP-4 inhibitor
aHR 1.09 (95% CI 0.91–1.31)

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeaHR (95% CI)
MOFsCurrent use0.89 (0.64–1.22)

Fractures at individual MOF sites

Risk similar with SGLT2 inhibitor vs DPP-4 inhibitor use

Duration of use, individual SGLT2 inhibitor agents, sex and age strata

No association with duration of SGLT2 inhibitor use (longest duration >811 days) for any individual agent, or after stratification by sex and age

Original publication

The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. Published 28 July 2023. doi:10.1111/dom.15220

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.